Posted by Michael Wonder on 15 Mar 2021
Melinta Therapeutics announces FDA approval of Kimyrsa (ortivancin) for the treatment of adult patients with acute bacterial skin and skin structure infections
15 March 2021 - Single dose antibiotic with one hour infusion, additional compatibilities in normal saline and D5W, and lower infusion volume.
Melinta Therapeutics today announced that the U.S. FDA has approved Kimyrsa (oritavancin) for the treatment of adult patients with acute bacterial skin and skin structure infections caused by susceptible isolates of designated Gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus.
